Alkermes Plc
ALKS32.890USD
+1.210+3.82%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
5.43BMarket Cap
16.03P/E TTM
More Details of Alkermes Plc Company
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Alkermes Plc Info
Ticker SymbolALKS
Company nameAlkermes Plc
IPO dateJul 16, 1991
CEOMr. Richard F. Pops
Number of employees1800
Security typeOrdinary Share
Fiscal year-endJul 16
AddressConnaught House
CityDUBLIN
Stock exchangeNASDAQ Global Select Consolidated
CountryIreland
Postal codeD04 C5Y6
Phone35317728000
Websitehttps://www.alkermes.com/
Ticker SymbolALKS
IPO dateJul 16, 1991
CEOMr. Richard F. Pops
Company Executives of Alkermes Plc
Name
Name/Position
Position
Shareholding
Change
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.29M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
205.37K
+0.55%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
103.74K
+3.84%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
69.74K
-5.42%
Mr. Brian P. Mckeon
Mr. Brian P. Mckeon
Independent Director
Independent Director
43.87K
+16.12%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
31.08K
+24.36%
Dr. Cato T. Laurencin, M.D., Ph.D.
Dr. Cato T. Laurencin, M.D., Ph.D.
Independent Director
Independent Director
29.10K
+26.46%
Dr. Christopher I. Wright, M.D., Ph.D.
Dr. Christopher I. Wright, M.D., Ph.D.
Independent Director
Independent Director
23.01K
+12.23%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Independent Director
Independent Director
10.71K
+131.91%
Dr. Nancy L. Snyderman, M.D.
Dr. Nancy L. Snyderman, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.29M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
205.37K
+0.55%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
103.74K
+3.84%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
69.74K
-5.42%
Mr. Brian P. Mckeon
Mr. Brian P. Mckeon
Independent Director
Independent Director
43.87K
+16.12%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
31.08K
+24.36%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
VIVITROL
121.66M
31.14%
ARISTADA
101.30M
25.93%
LYBALVI
84.28M
21.57%
Royalty Revenue - VUMERITY
32.02M
8.20%
Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA
30.32M
7.76%
Other
21.09M
5.40%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
VIVITROL
121.66M
31.14%
ARISTADA
101.30M
25.93%
LYBALVI
84.28M
21.57%
Royalty Revenue - VUMERITY
32.02M
8.20%
Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA
30.32M
7.76%
Other
21.09M
5.40%
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.37%
The Vanguard Group, Inc.
10.98%
T. Rowe Price Associates, Inc.
5.97%
State Street Investment Management (US)
4.97%
Baker Bros. Advisors LP
3.88%
Other
59.83%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.37%
The Vanguard Group, Inc.
10.98%
T. Rowe Price Associates, Inc.
5.97%
State Street Investment Management (US)
4.97%
Baker Bros. Advisors LP
3.88%
Other
59.83%
Shareholder Types
Shareholders
Proportion
Investment Advisor
53.57%
Investment Advisor/Hedge Fund
29.42%
Hedge Fund
14.45%
Research Firm
3.16%
Pension Fund
2.38%
Individual Investor
1.65%
Sovereign Wealth Fund
1.18%
Private Equity
0.61%
Bank and Trust
0.44%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
743
174.30M
105.56%
-28.06M
2025Q2
770
179.09M
108.49%
-26.85M
2025Q1
781
180.42M
109.41%
-27.12M
2024Q4
750
175.04M
107.61%
-39.68M
2024Q3
727
186.93M
115.42%
-33.14M
2024Q2
708
187.79M
113.20%
-24.77M
2024Q1
682
184.21M
108.96%
-28.40M
2023Q4
653
184.12M
110.36%
-5.13M
2023Q3
620
171.53M
102.92%
-4.71M
2023Q2
610
167.10M
100.38%
-17.86M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
23.73M
14.37%
-251.67K
-1.05%
Jun 30, 2025
The Vanguard Group, Inc.
18.45M
11.18%
+290.40K
+1.60%
Jun 30, 2025
T. Rowe Price Associates, Inc.
9.86M
5.97%
-1.76M
-15.13%
Jun 30, 2025
State Street Investment Management (US)
8.21M
4.97%
+185.59K
+2.31%
Jun 30, 2025
Baker Bros. Advisors LP
6.41M
3.88%
+1.93M
+42.99%
Jun 30, 2025
Renaissance Technologies LLC
5.81M
3.52%
+71.33K
+1.24%
Jun 30, 2025
RTW Investments L.P.
4.68M
2.84%
-2.20M
-31.99%
Jun 30, 2025
Geode Capital Management, L.L.C.
4.02M
2.44%
+83.86K
+2.13%
Jun 30, 2025
American Century Investment Management, Inc.
3.66M
2.22%
+191.55K
+5.53%
Jun 30, 2025
JP Morgan Asset Management
3.95M
2.39%
-179.85K
-4.36%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
AdvisorShares Psychedelics ETF
5.6%
iShares Neuroscience and Healthcare ETF
4.16%
Invesco S&P SmallCap Health Care ETF
3.15%
First Trust NYSE Arca Biotechnology Index Fund
3.08%
ALPS Medical Breakthroughs ETF
2.88%
Knowledge Leaders Developed World ETF
1.7%
Abacus FCF International Leaders ETF
1.46%
Langar Global HealthTech ETF
1.46%
SPDR S&P Biotech ETF
1.39%
Invesco S&P SmallCap Quality ETF
1.33%
View more
AdvisorShares Psychedelics ETF
Proportion5.6%
iShares Neuroscience and Healthcare ETF
Proportion4.16%
Invesco S&P SmallCap Health Care ETF
Proportion3.15%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.08%
ALPS Medical Breakthroughs ETF
Proportion2.88%
Knowledge Leaders Developed World ETF
Proportion1.7%
Abacus FCF International Leaders ETF
Proportion1.46%
Langar Global HealthTech ETF
Proportion1.46%
SPDR S&P Biotech ETF
Proportion1.39%
Invesco S&P SmallCap Quality ETF
Proportion1.33%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
